Roche Expands TL1A Development In A Catalyst-Rich Year
The company ended the year with financial momentum and will initiate clinical trials for its anti-TL1A in atopic dermatitis and MASH on top of late-stage studies ongoing in IBD.
The company ended the year with financial momentum and will initiate clinical trials for its anti-TL1A in atopic dermatitis and MASH on top of late-stage studies ongoing in IBD.